Home / Economy / News / India's coronavirus drug market set for price war as firms ready launches

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

Premium

A health official collects a swab sample from a woman to test for the Covid-19 inside a government school, in New Delhi. Photo: ANI

Sohini Das Mumbai

3 min read Last Updated : Jun 26 2020 | 8:14 AM IST

The Covid-19 cure drugs market in India is set for pricing competitions with multiple companies gearing up for launch. After Gilead’s injectable drug remdesivir, oral antiviral drug favipiravir is set to see some price erosion. Price erosion to the tune of 40 per cent is expected soon, industry says.

According to sources, companies such as Lupin are among the majors that are looking to launch favipiravir under their own brands after Glenmark launched its FabiFlu. Strides Pharma has already got approval from the Drug Controller General of India (DCGI) to conduct a bio-equivalence study on favipiravir in India. Cipla and

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in